leadf
logo-loader
RNS
viewErgomed PLC

Ergomed plc - Exercise of Share Options and Total Voting Rights

RNS Number : 0055V
Ergomed plc
04 August 2020
 

 PRESS RELEASE

 

 

Exercise of Share Options and Total Voting Rights

 

 

Guildford, UK - 4 August 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that, following an exercise of share options, application has been made to AIM for the admission of 50,000 new ordinary shares of 1p each in the capital of the Company (the "New Ordinary Shares").

 

Admission to trading on AIM of the New Ordinary Shares ("Admission") is expected to occur on 6 August 2020.  Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

 

Following Admission, the total number of ordinary shares with voting rights in issue will be 48,411,442. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Sue Stuart

[email protected]

Matthew Neal / Olivia Manser




 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCPJMBTMTJMTRM

Quick facts: Ergomed PLC

Price: 805

Market: AIM
Market Cap: £392.02 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Expansion of Modus study 'great news for Ergomed Plc'

Ergomed Plc (LON:ERGO) has been cheered by news of progress in a medical study by one of its co-development partners, Modus Therapeutics. The pharma services and drug development group drew its shareholders’ attention to an announcement by Modus relating to Sevuparin, a new drug to treat...

on 11/16/2016

3 min read